Vimarsana
Biggest News Aggregation in the World

Oncotype Test News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oncotype Test. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oncotype Test Today - Breaking & Trending Today

Mirae Asset Global Investments Co. Ltd. Boosts Holdings in Exact Sciences Co. (NASDAQ:EXAS) - Vimarsana News

Mirae Asset Global Investments Co. Ltd. Boosts Holdings in Exact Sciences Co. (NASDAQ:EXAS)

Mirae Asset Global Investments Co. Ltd. raised its position in Exact Sciences Co. (NASDAQ:EXAS – Get Rating) by 19.4% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 112,740 shares of the medical research company’s stock after buying an additional 18,357 shares during the quarter. Mirae Asset Global […]

Exact Sciences (NASDAQ:EXAS) vs. Viridian Therapeutics (NASDAQ:VRDN) Head-To-Head Analysis - Vimarsana News

Exact Sciences (NASDAQ:EXAS) vs. Viridian Therapeutics (NASDAQ:VRDN) Head-To-Head Analysis

Exact Sciences (NASDAQ:EXAS – Get Rating) and Viridian Therapeutics (NASDAQ:VRDN – Get Rating) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership. Insider and Institutional Ownership 94.5% of Exact Sciences shares are […]

Contrasting Viridian Therapeutics (NASDAQ:VRDN) & Exact Sciences (NASDAQ:EXAS) - Vimarsana News

Contrasting Viridian Therapeutics (NASDAQ:VRDN) & Exact Sciences (NASDAQ:EXAS)

Viridian Therapeutics (NASDAQ:VRDN – Get Rating) and Exact Sciences (NASDAQ:EXAS – Get Rating) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability. Volatility & Risk Viridian Therapeutics has a beta of 1.13, […]

Exact Sciences (NASDAQ:EXAS) Upgraded by StockNews.com to Hold - Vimarsana News

Exact Sciences (NASDAQ:EXAS) Upgraded by StockNews.com to Hold

Exact Sciences (NASDAQ:EXAS – Get Rating) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Saturday. Several other equities research analysts have also recently weighed in on EXAS. The Goldman Sachs Group dropped their price target on shares of Exact Sciences from $100.00 to $85.00 and […]

Genetron (NASDAQ:GTH) and Exact Sciences (NASDAQ:EXAS) Head-To-Head Analysis - Vimarsana News

Genetron (NASDAQ:GTH) and Exact Sciences (NASDAQ:EXAS) Head-To-Head Analysis

Exact Sciences (NASDAQ:EXAS – Get Rating) and Genetron (NASDAQ:GTH – Get Rating) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings. Institutional and Insider Ownership 94.5% of Exact Sciences shares are held […]